Atypical antipsychotics in improvement of Quality of life in Bipolar disorder - POLE

Study identifier:NIS-NKR-SER-2008/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 8-week, Multicenter, Open-label, Observational Study of Atypical antipsychotics in improvement of quality of life in Bipolar disorder

Medical condition

Naturalistic

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1000

Study type

Observational

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Nov 2008
Study Completion Date: 01 Nov 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria